Forma Therapeutics Holdings, Inc. (FMTX) NASDAQ
20.01
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
20.01
+0(+0.00%)
Currency In USD
Address
500 Arsenal Street
Watertown, MA 02472
United States of America (the)
Phone
617 679 1970
Sector
Healthcare
Industry
Biotechnology
Employees
189
First IPO Date
June 19, 2020
| Name | Title | Pay | Year Born |
| Frank D. Lee | Pres & Chief Executive Officer | 963,198 | 1968 |
| Todd E. Shegog | Senior Vice President & Chief Financial Officer | 620,246 | 1966 |
| David N. Cook | Senior Vice President & Chief Scientific Officer | 0 | 1958 |
| Jeannette Potts | Senior Vice President, Gen. Counsel & Corporation Sec. | 0 | 1962 |
| John E. Bishop | Senior Vice President & Chief Technology Officer | 0 | 1962 |
| Brian Lesser | Senior Vice President of Commercial | 0 | 1975 |
| Mario Vincent Corso | Head of Investor Relations | 0 | N/A |
| Linea Aspesi | Senior Vice President & Chief HR Officer | 0 | 1970 |
| Xuandai Nguyen | Vice President of Commercial Strategy & Marketing | 0 | N/A |
| Ifeyinwa Osunkwo | Senior Vice President & Chief Patient Officer | 0 | N/A |
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.